Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study
Shots:
- The in-vivo study was evaluated on group of rabbits administering bilateral intravitreal injection of Xlucane (ranibisumab- Lucentis biosimilar) vs Lucentis divided in two equal groups- testing its PK and tolerability in both the serum and the eyeglass body
- The results show Xlucane is well tolerated with no ocular inflammation in eyes- with equivalent PK observed in the serum and eyeglass body
- Xlucane is a mAb- being developed as biosimilar of Lucentis. Lucentis is approved for the treatment of Diabetic Retinopathy & Macular Edema- mCNV- Wet AMD and Macular Edema Following RVO
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
